Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $89.90 Consensus Price Target from Analysts

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have been given an average rating of “Buy” by the twelve ratings firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $89.90.

JANX has been the topic of several research reports. Scotiabank lifted their price objective on shares of Janux Therapeutics from $42.00 to $62.00 and gave the company a “sector perform” rating in a report on Wednesday, December 4th. BTIG Research upped their price objective on shares of Janux Therapeutics from $82.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, December 3rd. Leerink Partnrs raised Janux Therapeutics to a “strong-buy” rating in a research report on Friday, November 22nd. UBS Group assumed coverage on shares of Janux Therapeutics in a research note on Thursday, October 24th. They set a “buy” rating and a $69.00 price objective for the company. Finally, Stifel Nicolaus lifted their price objective on Janux Therapeutics from $70.00 to $115.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd.

Insider Activity at Janux Therapeutics

In related news, CEO David Alan Campbell sold 25,000 shares of Janux Therapeutics stock in a transaction on Friday, September 27th. The shares were sold at an average price of $46.31, for a total value of $1,157,750.00. Following the sale, the chief executive officer now owns 307,054 shares of the company’s stock, valued at approximately $14,219,670.74. This trade represents a 7.53 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Ventures Xi L.P. Avalon sold 958 shares of the company’s stock in a transaction on Monday, September 30th. The stock was sold at an average price of $46.24, for a total transaction of $44,297.92. Following the transaction, the insider now owns 6,887 shares of the company’s stock, valued at $318,454.88. This represents a 12.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 192,032 shares of company stock worth $9,512,515 in the last 90 days. Corporate insiders own 29.40% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Janus Henderson Group PLC raised its stake in Janux Therapeutics by 40.0% in the 3rd quarter. Janus Henderson Group PLC now owns 2,523,406 shares of the company’s stock valued at $114,587,000 after purchasing an additional 721,563 shares during the last quarter. Logos Global Management LP raised its position in shares of Janux Therapeutics by 400.0% in the second quarter. Logos Global Management LP now owns 750,000 shares of the company’s stock valued at $31,418,000 after buying an additional 600,000 shares during the last quarter. Point72 Asset Management L.P. lifted its stake in shares of Janux Therapeutics by 190.2% in the third quarter. Point72 Asset Management L.P. now owns 395,875 shares of the company’s stock worth $17,985,000 after buying an additional 259,445 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in Janux Therapeutics by 202.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company’s stock worth $10,639,000 after acquiring an additional 156,675 shares during the last quarter. Finally, Barclays PLC grew its stake in Janux Therapeutics by 496.5% during the 3rd quarter. Barclays PLC now owns 174,061 shares of the company’s stock valued at $7,907,000 after acquiring an additional 144,883 shares in the last quarter. 75.39% of the stock is owned by hedge funds and other institutional investors.

Janux Therapeutics Trading Down 0.1 %

Shares of NASDAQ:JANX opened at $56.75 on Friday. The firm’s 50-day moving average is $53.89 and its 200 day moving average is $47.05. Janux Therapeutics has a 12 month low of $7.79 and a 12 month high of $71.71. The company has a market capitalization of $2.98 billion, a price-to-earnings ratio of -48.50 and a beta of 3.29.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.18). The firm had revenue of $0.44 million during the quarter, compared to the consensus estimate of $1.50 million. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Janux Therapeutics’s quarterly revenue was down 82.6% compared to the same quarter last year. As a group, equities analysts forecast that Janux Therapeutics will post -1.35 EPS for the current fiscal year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.